Legal Representation
Attorney
Peter J. Lynfield
USPTO Deadlines
Application History
22 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Apr 28, 2014 | MAB2 | O | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | Loading... |
| Apr 28, 2014 | ABN2 | O | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | Loading... |
| Apr 28, 2014 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Sep 16, 2013 | CNRT | O | NON-FINAL ACTION MAILED | Loading... |
| Sep 14, 2013 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Aug 30, 2013 | ZZZX | Z | PREVIOUS ALLOWANCE COUNT WITHDRAWN | Loading... |
| Jul 19, 2013 | PBCR | Z | WITHDRAWN FROM PUB - OG REVIEW QUERY | Loading... |
| Jul 11, 2013 | PREV | O | LAW OFFICE PUBLICATION REVIEW COMPLETED | Loading... |
| Jul 11, 2013 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jun 20, 2013 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| May 30, 2013 | CNEA | O | EXAMINERS AMENDMENT MAILED | Loading... |
| May 30, 2013 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| May 30, 2013 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| May 6, 2013 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| May 6, 2013 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 6, 2013 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Nov 13, 2012 | CNRT | F | NON-FINAL ACTION MAILED | Loading... |
| Nov 12, 2012 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Nov 6, 2012 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jul 31, 2012 | MDSC | O | NOTICE OF DESIGN SEARCH CODE MAILED | Loading... |
| Jul 30, 2012 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jul 26, 2012 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations, namely, pharmaceutical preparations for the diagnosis and treatment of alcohol use disorders, Alzheimer's, anxiety disorders, atherosclerosis, autoimmune diseases and disorders, blood disorders, bone and skeletal diseases and disorders, cancer, cardiovascular diseases, central nervous system diseases and disorders, cholesterol disorders, cystic fibrosis, dementia, dermatological diseases and disorders, diabetes, dyslipidemia, endocrine diseases and disorders, gastrointestinal diseases and disorders, hormonal diseases and disorders, inflammation and inflammatory diseases and disorders, kidney diseases and disorders, liver diseases and disorders, metabolic diseases and disorders, migraines, muscle diseases and disorders, neurodegenerative diseases and disorders, neurological disorders, obesity, pain, pancreatic diseases and disorders, psychiatric disorders, reproductive system diseases and disorders, sleep disorders, urological disorders; antipsychotic pharmaceutical preparations; antidepressants
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Design Mark
The mark consists of a configuration of a three dimensional tablet in the shape of an irregular oval; with the word "Lilly" in script debossed on the face of the tablet; in the colors light yellow, with dark yellow on the sides of the tablet and framing the word "Lilly".
Color Claim
The color(s) light yellow and dark yellow is/are claimed as a feature of the mark.
Classification
International Classes
005